Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa

AIDS

Volumn 23, Issue 3, 2009, Pages 335-342

  Lawn, Stephen D ^a,b   Little, Francesca ^a   Bekker, Linda Gail ^a   Kaplan, Richard ^a   Campbel, Elizabeth ^a   Orrell, Catherine ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; Antiretroviral; Antiretroviral therapy; CD4; Death; HIV; Immune reconstitution; Immune recovery; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; LAMIVUDINE; STAVUDINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL FUNCTION; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SOUTH AFRICA; TREATMENT RESPONSE; VIROTHERAPY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; MALE; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 59849099091     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328321823f     Document Type: Article

References (28)

1. UNAIDS/WHO. AIDS epidemic update 2007. http://data.unaids.org/pub/ EPISIides/2007/2007-epiupdate-en.pdf.
2. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, et al. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. I Infect Dis 2008; 197:1324-1332.
3. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. progress report; 2007. http://www.who.int/hiv/mediacentre/universal-access-progress-report-en.pdf.
4. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
5. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low- income and high-income countries. Lancet 2006; 367:817-824.
6. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
7. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782- 793.
8. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006; 20:1181-1189.
9. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335-1342.
10. Zachariah R, Fitzgerald M, Massaquoi M, Pasulani O, Amould L, Makombe S, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006; 20:2355-2360.
11. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-2491.
12. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612.
13. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770- 776.
14. Bekker LG, Myer L, OrrelI C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006; 96:315-320.
15. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact within an antiretroviral treatment programme in sub- Saharan Africa. AIDS 2007; 21:335-341.
16. World Health Organisation. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach; Executive Summary. Geneva: World Health Organisation, Geneva; 2002.
17. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker LG, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12:83-88.
18. van Sighem Al, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17:2227-2236.
19. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1 -infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
20. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-224.
21. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R. Cryptococ- cocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2252.
22. Lawn SD, French MA. Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings. Curr Opin HIV/AIDS 2007; 2:339- 345.
23. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
24. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006; 6:59.
25. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19:2109-2116.
26. Lawn SD, Wood R. National adult antiretroviral therapy guidelines in South Africa: concordance with 2003 WHO guidelines? AIDS 2007; 21:121-122.
27. World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. WHO: Geneva.
28. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.